港股午评|恒生指数早盘涨1.29% 恒生生物科技指数大涨4.26%

Group 1 - The Hang Seng Index rose by 1.29%, gaining 301 points to close at 23,634 points, while the Hang Seng Technology Index increased by 1.32% and the Hang Seng Biotechnology Index surged by 4.26% [1] - Ningde Times (03750) saw a significant increase of over 16% on its first day of trading on the Hong Kong Stock Exchange [1] - 3SBio (01530) experienced a dramatic rise of 35%, nearing its historical high, following an authorization agreement with Pfizer for a PD-1/VEGF dual antibody, with Pfizer making an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] Group 2 - Yiming Anke-B (01541) rose over 10% after receiving a $5 million payment from Axion Bio, indicating a promising outlook in the self-immune field for IMM0306 [2] - Basilea Pharmaceuticals-B (02616) increased by over 18% after presenting five new research results at the 2025 AACR conference [2] - Rongchang Bio (09995) rose over 14% due to the addition of new indications for Vidi Xi monoclonal antibody, with Q1 performance slightly exceeding expectations [2] Group 3 - Xiaomi Group-W (01810) increased by nearly 4% ahead of the release of multiple new products, with its self-developed SoC "Xuanjie" expected to launch soon [5] - Alibaba Pictures (01060) surged over 17%, reporting an adjusted EBITDA profit of 809 million yuan for the year, a 61% year-on-year increase [6] - Alibaba Health (00241) fell over 4% post-earnings despite a more than 62% year-on-year increase in net profit, as it did not declare a final dividend [6]